Investor Presentaiton

Opdivo (anti-PD1) Early-Stage Trials Indication Peri-Adjuvant MIUC - Phase III CA 017-078 Phase/Study # of Patients N = 861 • Opdivo 360 mg Q3W for four cycles + chemotherapy Design Chemotherapy Primary: PCR, EFS Oncology Hematology Cell Therapy Immunology Cardiovascular Adjuvant HCC Phase III - CheckMate -9DX N = 545 Opdivo 480 mg Q4W Placebo • Primary: RFS Endpoints . Key secondary: OS Key secondary: OS Projected data readout 2025 • Projected data readout 2025 Status CT Identifier ll Bristol Myers Squibb Q3 2023 Results NCT03661320 NCT03383458 Not for Product Promotional Use 33

View entire presentation